Clinical Trial Update: Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of CX-3543 in patients with advanced solid tumors or lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• CX-3543 (CX-3543)

Snippet

Sponsor: Cylene Pharmaceuticals | Conditions: Advanced Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED